Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome (2024)

• •

  Mutant TP53 AML and MDS-EB do not differ with respect to molecular characteristics and survival.

• •

  Mutant TP53 AML/MDS-EB should be considered a single molecular disease entity.

Patients and samples

In total, 2200 patients with AML and MDS-EB (international prognostic scoring system [IPSS] ≥ 1.5 or revised IPSS > 4.5) were assessed for eligibility and treated in the Haemato-Oncology Foundation for Adults in the Netherlands and Swiss Group for Clinical Cancer Research (HOVON-SAKK) clinical trials between 2001 and 2017 (supplemental Figure 1 available on the Blood Web site). All patients received standard induction chemotherapy and were consolidated according to the HOVON-SAKK study protocols. Details of treatment protocols were described previously (www.hovon.nl).^{16, 17, 18, 19, 20, 21} All trial participants provided written informed consent in accordance with the Declaration of Helsinki. DNA was isolated from diagnostic bone marrow samples of 2200 patients with AML/MDS-EB and 537 CR samples (supplementary Methods). In 33 patients with AML/MDS-EB carrying TP53 variants with a variant allele frequency (VAF) >40%, DNA from saliva was available to verify the germline status.

Cytogenetics and SNP array analyses

Cytogenetic analysis was carried out at the local reference centers using standard protocols. These data, including karyotypes and FISH, were centrally peer-reviewed by clinical genetics laboratory specialists. The clonal structural and numerical chromosomal abnormalities were reported in accordance with the International System for Human Cytogenetic Nomenclature and the ELN 2017 recommendations.¹¹ CK was defined by 3 or more unrelated chromosome abnormalities in the absence of one of the World Health Organization–designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3), AML with BCR-ABL1.¹¹ Single nucleotide polymorphism (SNP) array was performed according to the manufacturer's instructions using Illumina Infinium GSA+MD-24 version 3.0 BeadChip (Illumina, Inc., San Diego, CA) on 134 of 230 mutant TP53 AML samples (110 bi-allelic and 24 mono-allelic mutants). The array was scanned with the Illumina iScan Control. Genome studio version 2.1 and Nexus Discovery version 10.0 (Biodiscovery, El Segundo, CA) were used for data analysis.

Targeted NGS and TP53 deep sequencing

The TruSight Myeloid Sequencing panel (Illumina) was used to detect the presence of driver mutations at diagnosis. Details were described previously.²² Only pathogenic TP53 variants were included as defined by occurrence in the COSMIC and IARC TP53 database as well as by analyses in silico with programs such as Polyphen-2, SIFT, FATHMM, MetaSVM, MetaLR, CADD, DANN, and ClinVar. The limit of detection was VAF 1% at diagnosis. To detect TP53 mutations in CR, we used Illumina-based deep sequencing (supplementary Methods). The limit of detection in the follow-up samples was VAF 0.001% (variable depending on TP53 mutation type). In the case of multiple TP53 mutations, the highest VAF was chosen for MRD analysis. Of note, patients with TP53 germline mutations were excluded from MRD assessment (n = 2).

Allocation of patients based on TP53 mutant allelic status

Patients with mutant TP53 AML/MDS-EB were considered bi-allelic when (1) 2 or more TP53 gene variants were detected, regardless of the VAF; (2) at least 1 TP53 gene variant co-occurred with a cytogenetic aberration involving chromosome 17p (eg, abnormality of 17p or monosomy 17); or (3) TP53 mutations were detected with a VAF >55% (supplemental Figure 2). The allocation to the bi-allelic mutant TP53 group by a VAF threshold of >55% was confirmed in all 15 of 110 patients with bi-allelic mutant TP53 AML that could be evaluated for copy number alterations by SNP array analyses (ie, either loss of the wild-type allele or segmental uniparental disomy of the mutant TP53 allele).

Statistical analysis

Associations between variables were tested by the Fisher's exact test for categorical variables and by the Mann-Whitney U test for continuous variables. The primary endpoint of the study was overall survival, defined as death from any cause. Survival time was calculated from the start of induction chemotherapy until the event of interest or censoring. Of note, the survival time in the analysis evaluating allogeneic HSCT started at the date of transplant. To compare the survival distributions, we used the log-rank test and the Cox proportional hazards model. The proportional hazards assumption was tested by interaction with time. All P values were two sided, and P values <.05 were considered statistically significant. Statistical analyses were executed with Stata Statistical Software, Release 16.0 (College Station, TX).

Molecular characteristics of mutant TP53 AML and MDS-EB

We detected 283 TP53 mutations in 230 of 2200 (10.5%) patients with AML/MDS-EB by NGS (Table 1; supplemental Figure 1). Of 230 patients with AML/MDS-EB, 44 (19%) were diagnosed with MDS-EB. No significant difference in age, sex, white blood cells, remission rate, and consolidation treatment was present between AML and MDS-EB (Table 1). Deletion 5q was the only cytogenetic aberration significantly more frequently present in MDS-EB (P = .025). Of note, in 112 patients with mutant TP53 AML/MDS-EB, concurrent chromosomal aberrations involving TP53 (eg, abnormality 17p or loss of chromosome 17) were detected.

Two or more TP53 mutations were found in 49 AML/MDS-EB cases (Table 2; supplemental Figure 2). In total, 206 missense, 16 nonsense, 38 insertion/deletion, and 23 splice-site mutations were detected (supplemental Figure 3). Nearly all missense mutations occurred in the TP53 DNA binding domain (supplemental Figure 3). In total, 56 of the 230 patients with TP53 mutant AML/MDS-EB (24.3%) were considered mono-allelic and 174 (75.7%) were bi-allelic (Table 2; supplemental Figure 2). The mutant TP53 clone size was normally distributed with a median VAF of 47% (supplemental Figure 4A). Concurrent mutations were detected in only 113 (49%) patients with mutant TP53 AML/MDS-EB (Figure 1). The most frequent concurrent mutations were detected in DNMT3A, TET2, ASXL1, RUNX1, and SRSF2 (Figure 1; Table 2). The TP53 mutant allelic status, number of TP53 mutations, TP53 clone size, and concurrent mutations at diagnosis did not significantly differ between mutant TP53 AML and MDS-EB (Table 2).

Of note, most (84%) patients with mutant TP53 AML/MDS-EB have CK, and many associations between CK and the different molecular characteristics were observed (Table 1; supplemental Table 1). CK was detected in most patients with bi-allelic mutant TP53 (97%), in patients with multiple TP53 mutations (94%), and in patients with larger TP53 clones (94% in VAF >40%) (supplemental Table 1; supplemental Figure 4B). Concurrent mutations were enriched in AML/MDS-EB marked by non-CK, yet the most prevailing mutated genes (DNMT3A and TET2) were not significantly associated with CK (supplemental Table 1).

Association of mutant TP53 characteristics and outcome in AML and MDS-EB

We next compared outcome of patients with mutant TP53 AML/MDS-EB in relation to the established ELN 2017 prognostic subgroups. Mutant TP53 strongly associated with reduced survival in the context of the ELN 2017 adverse risk category (2-year overall survival, 12.8% TP53 mutant vs 42.5% TP53 wild-type; P < .001) (Figure 2A). Because of the molecular hom*ogeneity of mutant TP53 AML and MDS-EB, we investigated whether the AML or MDS-EB status associated with survival. No difference in outcome was observed between the AML and MDS-EB mutant TP53 subgroups (P = .549) (Figure 2B). All our findings indicate that mutant TP53 AML/MDS-EB represents a hom*ogeneous group and is therefore considered a singular entity in the following analysis.

We performed survival analysis to evaluate the relationship of molecular characteristics and cytogenetic aberrations to outcome in mutant TP53 AML/MDS-EB. Mono-allelic mutant TP53 AML/MDS-EB had a similar dismal survival compared with its bi-allelic counterpart (P = .327) (Figure 3A; supplemental Figure 5). Neither the number of TP53 mutations (Figure 3B) nor aberrations involving chromosome 17 (supplemental Figure 6) associated with altered outcome in patients with mutant TP53 AML/MDS-EB. Concurrent mutations conferred limited but detectable survival benefit (Figure 3C), whereas the presence of specific concurrent mutations provided no further survival advantage (supplemental Figure 7). Clone size, realized by taking decreasing TP53 mutation VAF thresholds and continuous modeling per 10% VAF, was investigated for impact on outcome. None of the mutant TP53 VAF thresholds significantly associated with survival: VAF 50% (P = .990); VAF 40% (P = .257); VAF 30% (P = .064); VAF 20% (P = .189); VAF 10% (P = .161); and VAF 5% (P = .226) (supplemental Figure 8A-F) (hazard ratio per 10% VAF, 1.04; 95% CI, 0.99-1.09; P = .141). Hence, the molecular characteristics of mutant TP53 AML/MDS-EB did not evidently relate to treatment outcome.

In line with previous work, we confirmed that CK associates with reduced survival in TP53 mutant AML/MDS-EB (2-year overall survival, 9% CK vs 34% non-CK; P = .002), regardless of type of consolidation therapy (Figure 4).^{9, 10} However, the overall survival of patients with non-CK TP53 mutant AML/MDS remains poor. Because of strong association of CK with all mutant TP53 molecular characteristics, no further stratification was feasible among patients with AML/MDS-EB with CK (supplemental Table 1). Of note, CK AML/MDS-EB with wild-type TP53 appeared to have a significantly improved outcome in our cohort of 2200 AML/MDS-EB cases as compared with CK in the context of mutant TP53 (Figure 4C), indicating that the presence of mutant TP53 at diagnosis defines a separate CK entity.

Sensitivity analysis, performed to identify potential treatment modification within trial protocols, yielded no significant interactions. Similar results were obtained when elderly patients with AML were excluded (data not shown).

Molecular minimal residual disease in mutant TP53 AML

Detection of molecular MRD is an important prognostic marker in AML.^{22, 23, 24} We performed deep targeted sequencing on complete morphological remission bone marrow samples from 62 patients with mutant TP53 AML to assess molecular MRD. Mutant TP53 is often the only suitable marker for molecular MRD detection because the prevalence of concurrent mutations at diagnosis is relatively low and most concurrently mutated genes may associate with antecedent clonal hematopoiesis (DNMT3A, TET2, and ASXL1) rather than residual leukemia (Figure 1). In total, 45 of 62 patients with AML/MDS-EB had detectable TP53 mutations in CR, for which the status did not associate with overall survival (P = .653) (Figure 5).

The authors thank all the participating centers of the Dutch–Belgian Cooperative Trial Group for Hematology–Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK), where the clinical trials that formed the basis for this study were conducted; Eric Bindels for performing next-generation sequencing; Remco Hoogenboezem for assisting with bioinformatics; and Egied Simons for assisting with preparation of the figures (Erasmus University Medical Center).

This work was supported by grants from the Dutch Cancer Society “Koningin Wilhemina Fonds” (2020-12507). A.S.A.A.H. is a recipient of a PhD scholarship from the Ministry of Health of the Sultanate of Oman.

The online version of this article contains a data supplement.

There is a Blood Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisem*nt” in accordance with 18 USC section 1734.

Grob et al performed next-generation sequencing on 2200 samples from patients with acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) to assess the prognostic impact of TP53 mutation. Mutant TP53 occurred in 10.5% of AML/MDS-EB patients with concurrent mutations in half of them. All patients with TP53 mutations had poor outcomes, with a 2-year survival of only 12.8%, with no difference in outcome between AML and MDS-EB. The authors proposed that TP53-mutated AML/MDS-EB should be considered a distinct, single disease entity.

Supplement File 1:

1. Ley TJ, Miller C, Ding L, et al.Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. [PMC free article] [PubMed] [Google Scholar]

2. Metzeler KH, Herold T, Rothenberg-Thurley M, et al.AMLCG Study Group Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686–698. [PubMed] [Google Scholar]

3. Welch JS. Patterns of mutations in TP53 mutated AML. Best Pract Res Clin Haematol. 2018;31(4):379–383. [PMC free article] [PubMed] [Google Scholar]

4. Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30(3):666–673. [PMC free article] [PubMed] [Google Scholar]

5. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4(3):482–495. [PMC free article] [PubMed] [Google Scholar]

7. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552–555. [PMC free article] [PubMed] [Google Scholar]

8. Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599–604. [PMC free article] [PubMed] [Google Scholar]

9. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–2121. [PubMed] [Google Scholar]

10. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. [PMC free article] [PubMed] [Google Scholar]

11. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. [PMC free article] [PubMed] [Google Scholar]

12. Ciurea SO, Chilkulwar A, Saliba RM, et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018;131(26):2989–2992. [PMC free article] [PubMed] [Google Scholar]

13. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549–1556. [PMC free article] [PubMed] [Google Scholar]

14. Prochazka KT, Pregartner G, Rücker FG, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104(3):516–523. [PMC free article] [PubMed] [Google Scholar]

15. Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681–5689. [PMC free article] [PubMed] [Google Scholar]

16. Pabst T, Vellenga E, van Putten W, et al.Swiss Collaborative Group for Clinical Cancer Research (SAKK) Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012;119(23):5367–5373. [PubMed] [Google Scholar]

17. Löwenberg B, Pabst T, Maertens J, et al.Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017;129(12):1636–1645. [PubMed] [Google Scholar]

18. Ossenkoppele GJ, Breems DA, Stuessi G, et al.Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia. 2020;34(7):1751–1759. [PubMed] [Google Scholar]

19. Janssen J, Löwenberg B, Manz M, et al. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and High Risk MDS. Cancers (Basel). 2021;13(4):672. [PMC free article] [PubMed] [Google Scholar]

20. Löwenberg B, Pabst T, Maertens J, et al. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021;5(4):1110–1121. [PMC free article] [PubMed] [Google Scholar]

21. Dutch–Belgian Cooperative Trial Group for Hematology–Oncology,. http://www.hovon.nl. Accessed 1 November 2021.

22. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199. [PubMed] [Google Scholar]

23. Morita K, Kantarjian HM, Wang F, et al. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36(18):1788–1797. [PMC free article] [PubMed] [Google Scholar]

24. Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703–1713. [PMC free article] [PubMed] [Google Scholar]

25. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487. [PMC free article] [PubMed] [Google Scholar]

26. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. [PMC free article] [PubMed] [Google Scholar]